SKNV has licensed a Washington University patent portfolio covering the fluorouracil-calcipotriene combination increasingly recognized as one of the most promising field therapies for actinic keratosis, moving academic work on tissue-resident anti-tumor immunity into commercial practice through the compounding market. No financials related to the deal were disclosed.
The deal lands as the American Academy of Dermatology has updated its guidance to favor field-directed therapy for actinic keratosis over lesion-by-lesion treatment, citing the approach's potential to reduce progression to squamous cell carcinoma. Fluorouracil-calcipotriene combination therapy is central to that shift: the International Immunosuppression and Transplant Skin Cancer Collaborative recommended a short course of the combination for AK management in April 2026, based largely on data generated by the Washington University and Massachusetts General Hospital researchers who hold the underlying patents.
The combination pairs two long-approved single agents rather than introducing a new molecular entity. Fluorouracil, a cytotoxic antimetabolite, triggers immunogenic cell death and tumor-antigen release from sun-damaged keratinocytes. Calcipotriene, a vitamin D receptor agonist, drives thymic stromal lymphopoietin-mediated CD4+ T-cell infiltration into treated skin. Washington University's Lynn Cornelius and Massachusetts General Hospital's Shawn Demehri, co-inventors on the underlying IP, published data in the Journal of Clinical Investigation showing the combination reduced AK lesion counts after four days of treatment, versus the two-to-four-week course typically required for fluorouracil monotherapy. A follow-up study tracking the same trial cohort for more than 1,500 days linked the short course to reduced squamous cell carcinoma incidence on treated face and scalp sites, an effect the researchers associated with persistence of tissue-resident memory T cells.
Unlike an FDA-approved combination product, Kefunova is supplied through SKNV's FDA-registered 503B outsourcing facility, allowing commercialization without a separate NDA but limiting the labeling claims the company can make.